Microbiome health company Biome Australia Limited (ASX: BIO) has unveiled positive clinical trial results following the recent publication of a successful study completed in Italy using the probiotic strains in the company’s Biome Breathe Probiotic on paediatric asthma patients.
The results of the Probiotic in Paediatric Asthma Management (PROPAM) Study have now been published in the Journal of Immunology Research and clinically validate the company’s Biome Breathe Probiotic product making it one of the first probiotics globally to be scientifically proven to show an improvement in the symptoms of asthma in children.
This randomised placebo-controlled double-blind clinical trial assessed the efficacy of two specific probiotic strains in Biome Breathe™ Probiotic, L. salivarius LS01 and B. breve B632, in reducing the symptoms of asthma in 422 children over an eight week period in primary care settings, such as GP clinics.
The PROPAM study found that the group of children who took the combination of probiotic strains found in Biome Breathe Probiotic experienced 64.2% fewer exacerbations of their asthma symptoms, compared to the group of children who took placebo.
The authors concluded “the finding that probiotic strains… can reduce asthma exacerbations in children provides a potential complementary therapy for primary care physicians.”
This ground-breaking clinical trial is the independent research supporting the efficacy of Biome Australia’s Biome Breathe Probiotic, which was released into the Australian market following the receipt of promising pre-publication results.
Biome Breathe Probiotic contains this combination of probiotic strains and is available across Australia in over 2300 community pharmacies and independent health practitioners.
Biome Australia Managing Director and Founder Blair Norfolk said the release of these results demonstrating that the specialised probiotic strains in Biome Breathe can be used to effectively assist in the treatment of asthma in children is a major milestone for us and the health industry. “The clinical validation provides significant commercial opportunities for us to work closely with and expand our network of healthcare practitioners to improve the quality of life for asthma patients,” Mr Norfolk said.